Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.

Autor: Vermersch, Patrick, Brieva-Ruiz, Luis, Fox, Robert J., Paul, Friedemann, Ramio-Torrenta, Lluis, Schwab, Matthias, Moussy, Alain, Mansfield, Colin, Hermine, Olivier, Maciejowski, Maciej, Hecham, N., Deri, N. Haydeé, Djelilovic-Vranic, J., Milanov, I., Shotekov, P., Blevins, G., Girard, J., Lapierre, Y., Camu, W., Castelnovo, G.

Publikováno v: Neurology® Neuroimmunology & Neuroinflammation; May2022, Vol. 9 Issue 3, p1-12, 12p

Sodium intake and multiple sclerosis activity and progression in BENEFIT

Autor: Fitzgerald, Kathryn C., Munger, Kassandra L., Hartung, Hans peter, Freedman, Mark S., Montalbã¡n, Xavier, Edan, Gilles, Wicklein, Eva maria, Radue, Ernst wilhelm, Kappos, Ludwig, Pohl, Christoph, Ascherio, Alberto, Strasser fuchs, S., Berger, T., Vass, K., Sindic, C., Dubois, B., Dive, D., Debruyne, J., Metz, L., Rice, G., Duquette, P., Lapierre, Y., Freedman, M., Traboulsee, A., O'Connor, P., Å touraä, P., Talab, R., Zapletalova, O., Kovaå™ova, I., Medova, E., Fiedler, J., Frederiksen, J., Brochet, B., Moreau, T., Vermersch, P., Pelletier, J., Edan, G., Clanet, M., Clavelou, P., Lebrun frenay, C., Gout, O., Kallela, M., Pirttila, T., Ruutiainen, J., Koivisto, K., Reunanen, M., Elovaara, I., Villringer, A., Altenkirch, H., Wessel, K., Hartung, H. . P., Steinke, W., Kã¶lmel, H., Oschmann, P., Diem, R., Dressel, A., Hoffmann, F., Baum, K., Jung, S., Petereit, H., Reske, D., Sailer, M., Kohler, J., Sommer, N., Hohlfeld, R., Henn, K. . H., Tumani, H., Gold, R., Rieckmann, P., Komoly, R., Gacs, G., Jakab, G., Csiba, L., Vecsei, L., Miller, A., Karussis, D., Chapman, J., Ghezzi, A., Gallo, P., Cosi, V., Durelli, L., Anten, B., Visser, L., Myhr, K. . M., Szczudlik, A., Selmaj, K., Stelmasiak, Z., Podemski, R., Maciejek, Z., Cunha, L., Sega jazbec, S., Montalban, X., Arbizu, T., Saiz, A., Barcena, J., Arroyo, R., Fernandez, O., Izquierdo, G., Casanova, B., Lycke, J., Kappos, L., Mattle, H., Beer, K., Coleman, R., Chataway, J., Riordan, J. O., Howell, S., COMI, GIANCARLO

Objective: To assess whether a high-salt diet, as measured by urinary sodium concentration, is associated with faster conversion from clinically isolated syndrome (CIS) to multiple sclerosis (MS) and MS activity and disability. Methods: BENEFIT was a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_____10495::868859a433f78d5befd6c2b5551839ca
Wiley Online Library

Randomized controlled trial of interferon-beta-1a in secondary progressive MS - Clinical results

Autor: King, J, McLeod, J, Gonsette, R, Duquette, P, Ebers, G, Rice, G, Francis, G, Lapierre, Y, Freedman, MS, Oger, J, Paty, D, Sorensen, P, Pelletier, J, Hommes, O, Jongen, P, Sanders, E, Andersen, O, Wollheim-Sandberg, M, Chofflon, M, Bates, D, Barnes, D, Blumhardt, L, Hawkins, C, Hughes, R, Palace, J

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::cbbd4caf9a35c6ccc9ef8b758be5ca74
https://doi.org/10.1212/wnl.56.11.1496

INTERFERON BETA-1B IN THE TREATMENT OF MULTIPLE-SCLEROSIS - FINAL OUTCOME OF THE RANDOMIZED CONTROLLED TRIAL

Autor: Duquette, P, Despault, L, Knobler, R, Lublin, F, Kelley, L, Francis, G, Freedman, M, Lapierre, Y, Greenstein, J, Mishra, B, Delillio, N, Whitaker, J, Layton, B, Sibley, W, Laguna, J, Krikawa, J, Paty, D, Oger, J, Kastrukoff, L, Morrison, W, Nelson, J, Goodin, D, Massa, S, Gutteridge, E, Arnason, B

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::a2f1b7542488dd044ee9c1603bb77653
https://ora.ox.ac.uk/objects/uuid:205c2be5-9239-483c-ac75-c71b99307e11

Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome

Autor: Hartung, Hp, Strasser Fuchs, S, Berger, T, Vass, K, Sindic, C, Dubois, B, Dive, D, Debruyne, J, Metz, L, Rice, G, Duquette, P, Lapierre, Y, Freedman, M, Traboulsee, A, O'Connor, P, Stourac, P, Taláb, R, Zapletalová, O, Kováøová, I, Medová, E, Fiedler, J, Frederiksen, J, Brochet, B, Moreau, T, Vermersch, P, Pelletier, J, Edan, G, Clanet, M, Clavelou, P, Lebrun Frenay, C, Gout, O, Kallela, M, Pirttilä, T, Ruutiainen, J, Koivisto, K, Reunanen, M, Elovaara, I, Villringer, A, Altenkirch, H, Wessel, K, Steinke, W, Kölmel, H, Oschmann, P, Diem, R, Dressel, A, Hoffmann, F, Baum, K, Jung, S, Petereit, Hf, Reske, D, Sailer, M, Köhler, J, Sommer, N, Hohlfeld, R, Henn, Kh, Steinbrecher, A, Tumani, H, Gold, R, Rieckmann, P, Komoly, R, Gács, G, Jakab, G, Csiba, L, Vécsei, L, Miller, A, Karussis, D, Chapman, J, Ghezzi, A, Comi, G, Gallo, Paolo, Cosi, V, Durelli, L, Anten, B, Visser, L, Myhr, Km, Szczudlik, A, Selmaj, K, Stelmasiak, Z, Podemski, R, Maciejek, Z, Cunha, L, Sega Jazbec, S, Montalba, X, Arbizu, T, Saiz, A, Bárcena, J, Arroyo, R, Fernández, O, Izquierdo, G, Casanova, B, Lycke, J, Kappos, L, Mattle, H, Beer, K, Coleman, R, Chataway, J, O'Riordan, J, Howell, S. .

Publikováno v: Neurology, 77(9), 835-843. Lippincott Williams and Wilkins
Hartung, H P, Freedman, M S, Polman, C H, Edan, G, Kappos, L, Miller, D H, Montalban, X, Barkhof, F, Petkau, J, White, R, Sahajpal, V, Knappertz, V, Beckmann, K, Lanius, V, Sandbrink, R & Pohl, C 2011, ' Interferon beta-1b-neutralizing antibodies 5 years after clinically isolated syndrome ', Neurology, vol. 77, no. 9, pp. 835-843 . https://doi.org/10.1212/WNL.0b013e31822c90d7
Neurology, Vol. 77, no.9, p. 835-43 (2011)

To determine the frequency and consequences of neutralizing antibodies (NAbs) in patients with a first event suggestive of multiple sclerosis (MS) treated with interferon β-1b (IFNβ-1b).In the Betaseron/Betaferon in Newly Emerging MS For Initial Tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81e4a409371400c19a5e493cef1e8760
https://pubmed.ncbi.nlm.nih.gov/21849647